IQVIA (NYSE:IQV) Rating Increased to Buy at Wall Street Zen

Wall Street Zen upgraded shares of IQVIA (NYSE:IQV) from a hold rating to a buy rating in a research report report published on Saturday morning.

A number of other research firms have also recently issued reports on IQV. Evercore reissued an “outperform” rating and set a $225.00 target price on shares of IQVIA in a research note on Thursday, February 5th. JPMorgan Chase & Co. reduced their price objective on IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a research report on Friday, February 6th. UBS Group decreased their price objective on IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a report on Friday, February 6th. Citigroup cut their target price on IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research note on Friday, February 6th. Finally, Barclays decreased their price target on shares of IQVIA from $230.00 to $210.00 and set an “equal weight” rating for the company in a research note on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and a consensus price target of $235.20.

IQVIA Price Performance

Shares of IQV stock opened at $165.63 on Friday. The company has a quick ratio of 0.70, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. IQVIA has a 12-month low of $134.65 and a 12-month high of $247.04. The firm has a fifty day moving average of $217.61 and a 200-day moving average of $208.44. The firm has a market capitalization of $28.11 billion, a price-to-earnings ratio of 21.07, a price-to-earnings-growth ratio of 1.59 and a beta of 1.37.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, topping the consensus estimate of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The firm had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. During the same period in the previous year, the company posted $3.12 earnings per share. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, equities research analysts forecast that IQVIA will post 10.84 earnings per share for the current year.

Hedge Funds Weigh In On IQVIA

Institutional investors have recently added to or reduced their stakes in the company. Boston Partners bought a new position in shares of IQVIA in the 3rd quarter valued at about $676,698,000. Artisan Partners Limited Partnership bought a new position in IQVIA during the second quarter worth about $515,772,000. Norges Bank acquired a new position in IQVIA during the fourth quarter worth approximately $497,445,000. Victory Capital Management Inc. raised its stake in IQVIA by 2,628.1% in the fourth quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock valued at $377,670,000 after buying an additional 1,614,063 shares during the period. Finally, Orbis Allan Gray Ltd lifted its position in shares of IQVIA by 96.5% in the fourth quarter. Orbis Allan Gray Ltd now owns 1,901,091 shares of the medical research company’s stock valued at $428,525,000 after buying an additional 933,554 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.